Somewhere between 1 in 250 and 1 in 300 people are walking around with a genetic condition that makes their LDL cholesterol dangerously high from birth, and in most countries, fewer than 1 in 100 of them have ever been diagnosed. This is familial hypercholesterolemia, and it might explain a lot about why some people's cholesterol never seems to respond the way it "should."
What Familial Hypercholesterolemia Actually Is
Familial hypercholesterolemia, or FH, is an inherited condition caused by a mutation in one of a few specific genes, most commonly the LDL receptor gene, along with APOB and PCSK9, the same genes we've covered elsewhere on this site in the context of cholesterol treatment. These mutations impair the body's ability to clear LDL cholesterol from the blood, so LDL levels run high from childhood onward, not gradually over decades like typical age-related high cholesterol.
Left unrecognized, this translates into a dramatically higher lifetime exposure to LDL, and a correspondingly higher risk of heart attacks at a young age, sometimes in someone's 30s or 40s rather than their 60s or 70s.
How to Know If You Might Have It
Because FH doesn't announce itself with obvious symptoms in most people, it's usually pieced together from a combination of clues rather than any single test. Here's what doctors actually look for.
- Family history of early heart disease. A parent, grandparent, or sibling who had a heart attack or needed a stent or bypass surgery at an unusually young age, generally before 55 in men or 60 in women, is one of the strongest clues.
- Very high LDL cholesterol. Adults with untreated LDL levels above roughly 190 mg/dL, or children with LDL above about 160 mg/dL, are flagged for further evaluation in most clinical criteria.
- Physical signs on the body. These are less commonly known but genuinely useful clues. Firm, painless nodules over tendons, particularly the Achilles tendon or the knuckles, are called tendon xanthomas and are considered a strong physical sign of FH. A pale or grayish ring around the edge of the cornea, called arcus cornealis, is also significant specifically when it appears in someone under 45. Yellowish, soft deposits around the eyelids, called xanthelasma, can be another visible clue, though this one is less specific to FH alone.
- Formal clinical scoring. Doctors often combine these clues using a validated tool called the Dutch Lipid Clinic Network criteria, which assigns points for family history, physical signs, and LDL level to estimate the likelihood of FH before confirming with genetic testing.
If several of these apply to you, particularly a family history of early heart disease combined with LDL that's stayed stubbornly high despite a reasonable diet and lifestyle, it's worth specifically asking your doctor about FH, rather than assuming your numbers are just "genetics" in a vague sense.
Genetic Testing: The Definitive Answer
Clinical clues can strongly suggest FH, but a genetic test confirms it directly by identifying the specific gene mutation. This matters beyond just the individual, since a confirmed diagnosis opens the door to cascade screening, testing close relatives who may carry the same mutation without knowing it, since each child of a parent with FH has roughly a 50 percent chance of inheriting it.
A Program Worth Knowing About
While researching this topic, our editorial team came across a genuinely encouraging example of how a country can tackle FH's underdiagnosis problem directly. In June 2025, Singapore's Ministry of Health launched a national FH genetic testing program, allowing doctors to refer citizens and permanent residents with sufficiently high LDL cholesterol for subsidized genetic testing. It isn't entirely free, patients typically pay a reduced fee after means-tested subsidies of up to 70 percent, further reduced through the country's national medical savings scheme, but it represents a meaningful, structured effort to close the diagnosis gap. Close relatives of anyone who tests positive are also eligible for further discounted cascade screening, directly applying the family-based detection approach clinicians have long recommended.
It's a useful example of what's possible when a health system treats an underdiagnosed genetic condition as a systemic problem worth solving, rather than leaving detection to chance.
Frequently Asked Questions
Q: If neither of my parents had early heart disease, can I still have FH?
It's less likely, but not impossible, since FH can occasionally arise from a new mutation, and family history isn't always well documented or known, particularly if a parent died of something else before their heart disease became apparent. High LDL alone still warrants attention even without a clear family history.
Q: Can lifestyle changes alone manage FH?
Generally not on their own. Because FH involves a fundamental problem with how the body clears LDL, most people with confirmed FH need medication, often started early and sometimes requiring combination therapy, alongside healthy lifestyle habits rather than instead of them.
Q: I don't have any tendon nodules or eye changes. Does that rule out FH?
No. These physical signs are useful when present, but many people with genetically confirmed FH never develop visible tendon xanthomas or corneal arcus at all, especially with modern, earlier treatment. Their absence doesn't rule anything out.
Key Takeaway
Familial hypercholesterolemia affects roughly 1 in 250 to 1 in 300 people, yet remains dramatically underdiagnosed almost everywhere it's been studied. The clues, a family history of early heart disease, persistently very high LDL, and sometimes visible signs like tendon nodules or a corneal ring, are often available well before a genetic test confirms anything. If your cholesterol has never responded the way it "should," or your family has a pattern of early heart problems, this is a conversation worth having directly with your doctor, not a possibility to quietly wonder about.
References
- Akioyamen LE, Genest J, Shan SD, et al. Estimating the Prevalence of Heterozygous Familial Hypercholesterolaemia: A Systematic Review and Meta-Analysis. BMJ Open. 2017;7(9):e016461. doi.org/10.1136/bmjopen-2017-016461
- Bouhairie VE, Goldberg AC. Familial Hypercholesterolemia. Cardiology Clinics. 2015;33(2):169-179. pmc.ncbi.nlm.nih.gov/articles/PMC4498853
- Sharma T, et al. The Value of Physical Signs in Identifying Patients With Familial Hypercholesterolemia in the Era of Genetic Testing. Journal of Cardiology. 2020. journal-of-cardiology.com/article/S0914-5087(20)30237-9
- Ministry of Health, Singapore. Launch of National Familial Hypercholesterolaemia Genetic Testing Programme. moh.gov.sg/newsroom/launch-of-national-familial-hypercholesterolaemia-genetic-testing-programme